Stromal cell–derived DEL-1 inhibits Tfh cell activation and inflammatory arthritis

Hui Wang,Xiaofei Li,Tetsuhiro Kajikawa,Jieun Shin,Jong-Hyung Lim,Ioannis Kourtzelis,Kosuke Nagai,Jonathan Korostoff,Sylvia Grossklaus,Ronald Naumann,Triantafyllos Chavakis,George Hajishengallis,Jonathan M. Korostoff

DOI: https://doi.org/10.1172/jci150578

IF: 19.456

2021-10-01

Journal of Clinical Investigation

Abstract:The secreted protein developmental endothelial locus 1 (DEL-1) regulates inflammatory cell recruitment and protects against inflammatory pathologies in animal models. Here, we investigated DEL-1 in inflammatory arthritis using collagen-induced arthritis (CIA) and collagen Ab–induced arthritis (CAIA) models. In both models, mice with endothelium-specific overexpression of DEL-1 were protected from arthritis relative to WT controls, whereas arthritis was exacerbated in DEL-1–deficient mice. Compared with WT controls, mice with collagen VI promoter–driven overexpression of DEL-1 in mesenchymal cells were protected against CIA but not CAIA, suggesting a role for DEL-1 in the induction of the arthritogenic Ab response. Indeed, DEL-1 was expressed in perivascular stromal cells of the lymph nodes and inhibited Tfh and germinal center B cell responses. Mechanistically, DEL-1 inhibited DC-dependent induction of Tfh cells by targeting the LFA-1 integrin on T cells. Overall, DEL-1 restrained arthritis through a dual mechanism, one acting locally in the joints and associated with the anti-recruitment function of endothelial cell–derived DEL-1; the other mechanism acting systemically in the lymph nodes and associated with the ability of stromal cell–derived DEL-1 to restrain Tfh responses. DEL-1 may therefore be a promising therapeutic for the treatment of inflammatory arthritis.

medicine, research & experimental